Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03535298 · ClinicalTrials.gov registry record · Phase 4

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

A Phase 4 study of Multiple Sclerosis (Relapsing Remitting), sponsored by The Cleveland Clinic.

Active
Registry status
Phase 4
Development phase
800
Enrollment target
20
Study locations

NCT03535298 is a Phase 4 study of Multiple Sclerosis (Relapsing Remitting) that is active but no longer recruiting, run by The Cleveland Clinic. The registered enrollment target is 800 participants, above the 535-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (50% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03535298, a Phase 4 study of Multiple Sclerosis (Relapsing Remitting), is active but no longer recruiting, sponsored by The Cleveland Clinic.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
800 participants
Enrollment target
20
Study locations

Study Summary

The DELIVER-MS study seeks to answer the question: Does early treatment with highly effective DMT improve the prognosis for people with MS? This is an area of significant controversy and no data currently exist to guide treatment choices for patients and clinicians. The study results will help guide overall treatment philosophy and will be applicable not only to a wide range of existing therapies but also to new therapies, meeting a significant unmet need in patient decision making and aiding the decision for medication approval by third parties.

Conditions Studied

Multiple Sclerosis (Relapsing Remitting)

Interventions

  • DRUG Early Highly Effective Therapies Group
  • DRUG Escalation Therapies Group

Study Locations (20)

England

  • University Hospitals Coventry and Warwickshire - Coventry
  • The Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary - Leeds
  • University Hospitals Leicester - Leicester
  • Imperial College Healthcare NHS Trust, Charing Cross Hospital - London
  • University College London Hospitals NHS Foundation Trust, University College Hospital - London

Ohio

  • University of Cincinnati - Cincinnati
  • Cleveland Clinic - Cleveland
  • Ohio Health - Columbus

Texas

  • UT-Austin - Austin
  • Baylor College of Medicine, Houston - Houston
  • UTHealth-Houston - Houston

Minnesota

  • University of Minnesota - Minneapolis
  • Mayo Clinic - Rochester

New York

  • University of Buffalo - Buffalo
  • University Rochester Medical Center - Rochester

Virginia

  • University of Virginia - Charlottesville
  • Virginia Commonwealth University - Richmond

Colorado

  • University of Colorado-Anschutz Medical Campus - Aurora

Nevada

  • Cleveland Clinic Lou Ruvo Center for Brain Health - Las Vegas

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2019-01-03
Est. Completion 2027-07-30
Phase Phase 4

Sponsor

The Cleveland Clinic

688 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03535298

The ClinicalTrials.gov registry entry for NCT03535298 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 535-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (50% higher). The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Sclerosis (Relapsing Remitting) appearing as the primary indexed condition, and to 2 interventions - of which Early Highly Effective Therapies Group is the first listed.

NCT03535298 reports 20 study locations spanning 9 distinct geographic areas - top geographies include England, Ohio, Texas.

Frequently Asked Questions

What is clinical trial NCT03535298 about?

NCT03535298 is a clinical study titled "Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS". The DELIVER-MS study seeks to answer the question: Does early treatment with highly effective DMT improve the prognosis for people with MS? This is an area of significant controversy and no data currently exist to guide treatment choices for patients and clinicians. The study results will help guide...

What is the current status of trial NCT03535298?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 800 participants. The study started on 2019-01-03. Estimated completion is 2027-07-30.

What conditions does trial NCT03535298 study?

This clinical trial studies the following conditions: Multiple Sclerosis (Relapsing Remitting).

What interventions are being tested in trial NCT03535298?

The interventions under investigation include: Early Highly Effective Therapies Group (DRUG), Escalation Therapies Group (DRUG).

Who is sponsoring clinical trial NCT03535298?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03535298 being conducted?

This trial has 20 study locations across Colorado, Minnesota, Nevada, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Sclerosis (Relapsing Remitting)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Sclerosis (Relapsing Remitting)

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.